Sareum (LON:SAR) Announces Earnings Results

Sareum (LON:SAR) issued its quarterly earnings data on Tuesday. The company reported GBX (0.90) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports.

Sareum Stock Up 9.6 %

Sareum stock traded up GBX 1.15 ($0.01) during midday trading on Thursday, hitting GBX 13.15 ($0.17). 1,004,110 shares of the stock were exchanged, compared to its average volume of 421,408. Sareum has a 52-week low of GBX 10 ($0.13) and a 52-week high of GBX 52.50 ($0.68). The business’s 50-day moving average price is GBX 17.82 and its 200-day moving average price is GBX 23.19. The stock has a market capitalization of £16.43 million, a price-to-earnings ratio of -3.11 and a beta of -1.08.

Insider Buying and Selling at Sareum

In other Sareum news, insider Stephen Parker bought 84,033 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average cost of GBX 12 ($0.15) per share, with a total value of £10,083.96 ($12,983.08). Company insiders own 5.02% of the company’s stock.

Sareum Company Profile

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.